HOME ·

02335.HK

MICOT PHARMA-B (02335.HK): H shares included in eligible list under Stock Connect
Tags：
Micot Pharma-B02335.HKStock Connect
2026-09-07
Micot (02335.HK): Phase‑II Clinical Trial of MT200605 for Acute Ischemic Stroke Completed, AKI Incidence Reduced by Over 80% in High‑dose Cohort
Tags：
Micot02335.HK
2026-08-27
MICOT PHARMA-B (02335.HK): To Be Included as Hang Seng Composite Index Constituent with Effect from 7 September
Tags：
Micot Pharma-B02335.HKIndex Inclusion
2026-08-24
MICOT PHARMA-B (02335.HK): Three XTL6001 Studies Accepted for Presentation at EASD 2026 and ASN Kidney Week 2026, Triple-Agonist Mechanism Gains International Recognition
Tags：
Micot Pharma-B02335.HKResearch Progress
2026-08-17
MICOT PHARMA-B (02335.HK): Preclinical and Phase I data of neuroprotective candidate MT200605 accepted for oral presentation at 2026 World Stroke Congress; Phase II meets primary endpoint
Tags：
Micot Pharma-B02335.HKR&D Progress
2026-08-11
Shaanxi Micot Pharmaceutical Technology (02335.HK): Phase II Trial of MT200605 for Acute Ischemic Stroke Meets Primary Endpoint
Tags：
Shaanxi Micot Pharmaceutical Technology02335.HK
2026-08-04
Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment
Tags：
Micot Pharma02335.HKClinical Trial
2026-07-09
MICOT PHARMA-B(02335.HK) closed 102.75% higher, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends
Tags：
Micot Pharma-B02335.HK
2026-06-24
Micot Pharma-B (02335.HK): Grey Market Surges 84.18% to HK$33.52
Tags：
Micot Pharma-B02335.HKGrey MarketIPO
2026-06-23
Micot Pharma-B (02335.HK) Launches IPO: Max Offer Price at HK$21.0, Entry Fee Around HK$4,242 per Lot
Tags：
Micot Pharma02335.HKIPO
2026-06-15